Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2017 - 12 - 29
点击次数: 0
Positions: Vice President
Company: Beijing Shenogen Biotech
个人简介:
Dr. Ye Graduated from Weizmann Institute Israel in 1998, followed by Post.Doc training in Harvard Medical School, was promoted as Assistant Professor in Brigham Women’s Hospital, affiliated Dana-Farber Cancer Center in 2008. He was awarded with several cancer Research grants including USA NIH  Grants.  Dr. Ye also  actively served Science committee, Education Committee in USA Society of Integrative Oncology, and as Editorial reviewer  of the high impact Journals,  including Journal Clinical Oncology, Journal Clinical Investigation, Cancer Research, and contributed more than 40 original research papers and review articles, Dr. Ye has 5 USA patents;Since 2011, Dr. Ye shift his career gear to more clinical and cancer  therapy,  Joined Novartis as Senior Investigator, Heading Novartis China Biomarker group, lead the translational research,  clinical trials and Biomarker outsourcing in GCLP compliance and industry standard.From 2014, Dr.Ye joined  Shenogen Pharma Group,  and now   serve as Vice President, actively leading the Clinical Biomarker Translation in Immune-Modulation therapy in advanced HCC.
发布时间: 2017 - 12 - 18
点击次数: 0
Positions: CFO and Chief Strategy Officer
Company: BeiGene
个人简介:
Howard Liang, Ph.D., CFO and Chief Strategy Officer of BeiGene, obtained his M.B.A. and Ph.D. in Biochemistry and Molecular Biology from The University of Chicago, and his B.S. in Chemistry from Peking University. Prior to joining BeiGene, Dr. Liang spent 10 years at Leerink Partners, where he was a Managing Director and Head of Biotechnology Equity Research. Dr. Liang also held positions including senior biotechnology analyst at AG Edwards and JMP Securities, and associate analyst at Prudential Securities, where he started his career on Wall street. Dr. Liang was granted the “Best of the Street” in Biotechnology & Pharmaceuticals and in Biotechnology by Wall Street Journal, Bloomberg Markets Top US Analysts in Biotechnology, and Institutional Investor All-America Research Team in Biotechnology / Mid- & Small-Cap. Before joining Wall Street, Dr. Liang spent eight years at Abbott Laboratories, where he was a senior scientist and a member of one of the industry’s leading structure-based drug discovery teams. During his career as a scientist, Dr. Liang authored a review and 13 papers including 6 in Nature, Science, and Proceedings of the National Academy of Sciences.
发布时间: 2017 - 12 - 18
点击次数: 0
Positions: Global Head of TCO Shanghai
Company: Novartis
个人简介:
Bin Peng received his MD degree from Sun Yet-sen University of Medical Sciences in Guangzhou, China. He then earned PhD of Cancer Clinical Pharmacology at Cancer Research Unit, University of Newcastle upon Tyne, UK  and completed postdoc- fellowship in Pharmaceutical School, Manchester University, UK . Then he joined Novartis Pharma AG, Basel, Switzerland as senior clinical pharmacologist. He has been involved in Gleevec (STI571, the first target chemotherapy drug for cancer treatment) entire clinical development from 1998 with the phase I study in man to the registration worldwide in 2001.  He joined CPDM/Oncology, GSK, USA as Director of Clinical Pharmacology in 2005. His research interests have focused on the Phase I, Cancer Translational Medicine, human PK/PD and early clinical development of anticancer and hematology drugs. He has authored more than 70 papers and abstracts on clinical pharmacology and early clinical investigation in the field of anticancer/hematology drugs. He re-joined oncology translational medicine (OTM) department, Novartis as global head of TCO Shanghai in 2009.
发布时间: 2017 - 12 - 18
点击次数: 0
Positions: Global VP and General Manager
Company: MSD R&D(China)Co.,Ltd
个人简介:
Zhengqing is the Vice President and Head of MSD China R&D. In this position, he is responsible for the operation and strategic direction of Merck’s R&D Center in Beijing. As the China R&D head, Zhengqing leads a development team whose primary mission is to bring innovative medicines and vaccines effectively and efficiently to meet unmet medical needs of Chinese patients. In addition, Zhengqing plays the leadership role in building Merck’s global capabilities inChinain the areas of quantitative sciences such as data management, biostatistics and epidemiology, and in establishing external collaborations with research institutes, professional societies and industry partners. Currently the MSD China R&D Center employs approximately 600 scientists with expertise across clinical research, regulatory affairs, clinical trial operations, pharmacovigilence, project management, biostatistics, epidemiology, and data management. Zhengqing has more than 20 years of Clinical trial and product development experience both in China and in the United States. Prior to joining MSD, Zhengqing took a number of leadership roles with Bristol-Myers Squibb (BMS) including the Head of Clinical Research, China R&D and Executive Director and Head of Oncology & Neuroscience, Global Biometric Sciences. Prior to joining BMS, Zhengqing also worked with Pfizer and Procter & Gamble Pharmaceutics with increasing responsibility in drug development.Zhengqing has authored and co-authored more than 40 scientific and clinical trial methodology papers and abstracts. He led or participated in the development and approval of more than 10 innovative products in China and United States. Recently he won the International Talent Award from Chao Yang District, Beijing Municipal Government.Zhengqing was born and grew up in China. He received his undergraduate education at University of Science and Technology of China and his PhD degree from University of Wisconsin-Madison with major in Biostatistics. Upon completion of his PhD, Zhengqing took a faculty position in the School of Public Health at State University of New York at Albany.
74页次10/19首页Previous...  567891011121314...Next尾页